Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Dec;29(12):796-798.
doi: 10.1016/j.clon.2017.10.007. Epub 2017 Oct 26.

The Application and Feasibility of Using Routine Data Sources for Long-term Cancer Clinical Trial Follow-up

I S Bhattacharya  1 , J P Morden  2 , C Griffin  2 , C Snowdon  2 , R Brannan  3 , J M Bliss  2 , L Kilburn  2
Affiliations
Editorial

The Application and Feasibility of Using Routine Data Sources for Long-term Cancer Clinical Trial Follow-up

I S Bhattacharya et al. Clin Oncol (R Coll Radiol). 2017 Dec.
No abstract available

PubMed Disclaimer

References

    1. Kumar HS. National Health Service Cancer Strategy for England: Where Are We Now? Clinical oncology (Royal College of Radiologists (Great Britain)) 2016;28(5):277–8. - PubMed
    1. Appleyard S, Gilbert DC. Innovative solutions for clinical trial follow-up: adding value from nationally held UK data. Clin Oncol. 2017;29:789e795. - PubMed
    1. Victora CG, Habicht JP, Bryce J. Evidence-based public health: moving beyond randomized trials. American journal of public health. 2004;94(3):400–5. - PMC - PubMed
    1. Kilburn LAM, Banerji J, Bliss J. Results of a retrospective linkage of TACT (CRUK 01/001) breast cancer trial data and the National Cancer Data Repository. National Cancer Research Institute (NCRI) Cancer Conference 2012; 4-7 Nov; Liverpool, UK. NCRI; 2012. Nov, Abstract A141. Available from: http://abstracts.ncri.org.uk/abstract/results-of-a-retrospective-linkage...
    1. Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology. 2017 - PMC - PubMed

Publication types

LinkOut - more resources